Milind Deshpande, PhD, is a Director of Clear Creek Bio. Milind is a Venture Partner at RA Capital and is a founder CEO of several RA Capital portfolio companies. Milind also serves as the Chairman of the Board of Directors of Spero Therapeutics, a publicly traded company developing novel antibiotics. Milind was the President, CEO, and Board member at Achillion Pharmaceuticals from 2013-2018. He joined Achillion in 2001, and led the R&D organization prior to assuming the role of President & CEO. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb, where he led discovery and development of clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Milind has published more than 80 peer-reviewed research articles and is a co-inventor in more than 40 patents, including 3 approved drugs. Milind received his PhD in organic chemistry from Ohio University, following his undergraduate education in India. 

585 Massachusetts Avenue
Cambridge, MA 02139
info@clearcreekbio.com